double the sales force since all other expenses are set. another 300 sales will cost rougly 10m per quarter.
it is crucial we get to break even by late 2014 to early 2015 imo. after that it will be smotth saling imo.
By any means, even using royalty of net sales or Vascepa license as the collateral -- in light of that the patents were collateralized for the $100M loan, let's get another collateralized loan (second mortgage?) or something else.
So, we get AMRN to send each of us 50 Vascepa brochures that we can deliver to every Cardiologist that we drive by. I made my 1st visit to a Card 3 weeks ago. His response was Vascepa, what is it ? He does routinely script Lovaza.
AMRN has an army of mad and financially hungry shareholders that are willing to lend a hand.
How about it ???